Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 59Leukemia 55Lymphoma, Non-Hodgkin 45Lymphoma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 43Multiple Myeloma 42Hodgkin Disease 38Hematologic Neoplasms 35Myeloproliferative Disorders 24Melanoma 22Lymphoma, Mantle-Cell 18Recurrence 17Lymphoma, Follicular 17Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Primary Myelofibrosis 14Lymphoma, B-Cell 14Burkitt Lymphoma 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, B-Cell, Marginal Zone 13Leukemia, Myelomonocytic, Chronic 13Leukemia, Biphenotypic, Acute 13Graft vs Host Disease 13Hematologic Diseases 12Anemia, Aplastic 11Skin Neoplasms 10Ovarian Neoplasms 10

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × fludarabine × Clear all
NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡